Skip to content
USPeptideRxLearnApply for an account

Operator Q&A

Can a med spa stock compounded drugs?

USPeptideRx EditorialLast reviewed:

Usually not — and the reason has little to do with med spas. Every office-use provision in the states reviewed here grants a permission to supply a licensed PRESCRIBER, not to a business entity buying inventory, so the question turns on the prescriber’s authority rather than on what the business is called. The two routes that do work are a 503B outsourcing facility and patient-specific fulfilment.

Why the answer is usually no

Federal law sets the floor. 21 U.S.C. § 353a(a) exempts a compounded drug from three federal requirements — current good manufacturing practice, adequate directions for use, and new drug approval — only when the drug is "compounded for an identified individual patient based on the receipt of a valid prescription order." Section 353a(a)(2) allows compounding "in limited quantities before the receipt of a valid prescription order" where there is an established prescribing history, and that stock is still dispensed against a patient-specific prescription when one arrives.

Office-use stock is by definition not patient-specific, and § 353a contains no lane that lets a 503A pharmacy — a state-licensed pharmacy — hand a practitioner non-patient-specific inventory. The federal side of this is set out in full in 503A vs 503B.

The rules run to the prescriber, not to the business

Every office-use provision reviewed here reads as a permission to supply a licensed prescriber. Georgia's rule governs "office use by a practitioner." North Carolina's authorises a pharmacy to supply "practitioners authorized by law to prescribe drugs." Illinois permits a pharmacist to "dispense and deliver a reasonable quantity of a nonsterile compounded drug to a practitioner for office use."

None of them describes a business entity purchasing inventory. The counterparty named in the text is the physician, nurse practitioner or physician assistant who holds prescribing authority — a different commercial relationship than a med spa buying retail product.

Does this apply to a clinic that isn't a med spa?

Yes, and for the same reason. Because the rule text names the prescriber rather than the business, the answer does not change when the sign on the door says primary care, wellness, longevity or hormone clinic. What changes the answer is the state, the prescriber's authority, and whether the preparation is sterile — not the business model or the entity type. A practice that employs its prescribers and a med spa that contracts with one face the same pharmacy rule; the difference between them shows up in licensure and corporate-practice questions that sit outside the compounding code and are not addressed here.

If your question is the underlying legal one rather than the purchasing one, is office-use compounding legal? answers it state by state.

What the verified states mean for a med spa

StateNon-patient-specific stock from a 503A pharmacy
GeorgiaProhibited for human practitioners; 503B facilities expressly carved out
New JerseyProhibited, sterile and non-sterile alike
LouisianaNot authorised for human use; the only lane is veterinary
OhioNarrow and legally contested
IllinoisNon-sterile only; sterile office use prohibited
North CarolinaPermitted under state pharmacy law, conditioned on federal law

Illinois draws its line between sterile and non-sterile, so there the classification of each specific preparation decides the answer. The full matrix — quantity caps, label legends, recordkeeping and board reporting — is in the state-by-state office-use guide, and each state page carries its rule text verbatim.

Does this cover products the practice already stocks?

Ohio handles this as a licensure question about the practice, not only a compounding question. Any business entity possessing dangerous drugs at a location needs a terminal distributor of dangerous drugs licence, and dangerous drugs expressly include injectable local anaesthetics and botulinum toxin.

The Board's guidance for prescriber practices engaged in compounding, updated 1/13/2025, states that "in general, the exemptions to Ohio's TDDD licensure requirements do not apply if the prescriber practice is engaged in drug compounding," then carves out five lower-risk activities that do not trigger licensure. Three are recognisable med spa activities: preparing a manufactured dermal filler per manufacturer labelling; reconstituting a manufactured botulinum toxin product for direct administration, with no intervening steps; and possessing compounded preparations provided by an Ohio-licensed outsourcing facility. The caveat in the same document is the operative sentence:

Preparation of such medications in advance of administration requires licensure and compliance with the Board's compounding rules.

The two routes that do work

A 503B outsourcing facility, which registers with the FDA. Georgia's rule says its office-use prohibition "shall not affect 503b outsourcing facilities ability to provide non-patient specific compounded preparations for office use by a practitioner." Illinois prohibits sterile office use unless the pharmacy is in full compliance with 21 U.S.C. § 353b — including registration as an outsourcing facility and licensure as an Illinois wholesale drug distributor under 225 ILCS 120. Ohio's own guidance names possession of 503B-supplied compounded preparations as an activity that does not trigger prescriber licensure.

Patient-specific fulfilment. The pharmacy compounds against a prescription written for a named patient and delivers to the practice for administration. Illinois says so expressly, and excludes that delivery from its own definition of office use.

What this means for your practice

If your plan is a refrigerator of non-patient-specific compounded vials, it is closed in Georgia, New Jersey and Louisiana, contested in Ohio, and limited to non-sterile preparations in Illinois. Ask any supplier for the rule text and the citation, not a summary. Two of these verdicts are routinely reported backwards: Georgia's rule says office use "is prohibited" in those words, and North Carolina's permission is expressly conditioned on compliance with applicable federal law — so neither state is the open door it is often described as.

One thing this page does not settle is which permit attaches to the purchase itself. That turns on whether the order is signed by your business entity or by a named practitioner under their own licence — a different question from whether the stock is lawful, with a different answer in Florida and California — and it is worked through for med spas.

If you want the two workable routes mapped against your state and your product list, you can apply for an account.

What this page does not establish

  • This page states the position in Georgia, North Carolina, Ohio, Louisiana, New Jersey and Illinois, each read in full from primary sources. A state not named here is unknown on this page — not permissive and not prohibited — and nothing here should be extrapolated to it.
  • Whether a 503B outsourcing facility may supply prescriber office stock has been verified in Georgia, Illinois and Ohio only. North Carolina, Louisiana and New Jersey were not checked on that point.
  • The New Jersey rule text is verified current as of a January 2025 capture and is self-dated May 2024. A later revision has not been ruled out.
  • Georgia’s nursing and medical board rules, and the equivalent rules in the other states named above, sit outside the pharmacy code and were not checked.
  • Nothing here describes any drug’s safety or effectiveness, and no statement about a compounded preparation’s therapeutic performance should be inferred from it.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.

  1. [1]21 U.S.C. § 353a — Pharmacy compounding (Cornell LII)
  2. [2]Ga. Comp. R. & Regs. r. 480-11-.02(1)(d) — Pharmaceutical Compounding
  3. [3]21 NCAC 46 .2801(c) — North Carolina Board of Pharmacy rules
  4. [4]Ohio Rev. Code § 4729.01(C)(5) — definition of compounding
  5. [5]Ohio Admin. Code 4729:7-2-03(E) — compliance with 21 U.S.C. § 353a
  6. [6]Ohio Board of Pharmacy — Terminal Distributor Requirements for Prescribers Engaged in Drug Compounding (updated 1/13/2025)
  7. [7]Ohio Board of Pharmacy — Terminal Distributor Licensure of Prescriber Practices (rev. 8/24/2023)
  8. [8]La. Admin. Code tit. 46, pt. LIII, § 2535 — Compounding of Drugs
  9. [9]N.J.A.C. 13:39-11.18 and 13:39-11A.6 — State Board of Pharmacy (archived capture, 2025-01-21)
  10. [10]68 Ill. Adm. Code 1330.640 — Pharmaceutical Compounding Standards